Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease

Next Previous
Trial Profile

Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Emotional lability
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 10 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017.
    • 01 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top